Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004–2014

被引：0
|
作者：
Ming Wang
Emily Wasserman
Nathaniel Geyer
Rachel M. Carroll
Shanshan Zhao
Lijun Zhang
Raymond Hohl
Eugene J. Lengerich
Alicia C. McDonald
机构：
[1] Penn State College of Medicine and Cancer Institute,Department of Public Health Sciences
[2] Penn State Cancer Institute,Department of Mathematics and Statistics
[3] the University of North Carolina at Wilmington,Department of Pharmacology
[4] Biostatistics and Computational Biology Branch,undefined
[5] National Institute of Environmental Health Sciences,undefined
[6] Penn State Institute of Personalized Medicine,undefined
[7] Penn State Milton S. Hershey Medical Center,undefined
[8] Penn State College of Medicine,undefined
来源：
BMC Cancer | / 20卷
关键词：
Prostate cancer; Mortality; Spatial heterogeneity; Catchment area; Accelerated failure time models;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy
    Buyyounouski, Mark K.
    Hanlon, Alexandra L.
    Horwitz, Eric M.
    Pollack, Alan
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 70 (01): : 59 - 66
  • [42] Estimating Heritability of Prostate Cancer-Specific Survival Using Population-Based Registers
    Szulkin, Robert
    Clements, Mark S.
    Magnusson, Patrik K. E.
    Wiklund, Fredrik E.
    Kuja-Halkola, Ralf
    PROSTATE, 2017, 77 (08) : 900 - 907
  • [43] Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008
    Oberaigner, Willi
    Siebert, Uwe
    Horninger, Wolfgang
    Klocker, Helmut
    Bektic, Jasmin
    Schaefer, Georg
    Frauscher, Ferdinand
    Schennach, Harald
    Bartsch, Georg
    INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2012, 57 (01) : 57 - 62
  • [44] Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM)
    Russo, Andrea L.
    Chen, Ming-Hui
    Aizer, Ayal A.
    Hattangadi, Jona A.
    D'Amico, Anthony V.
    BJU INTERNATIONAL, 2012, 110 (07) : 973 - 979
  • [45] Patterns of care and treatment trends for Canadian men with localized low-risk prostate cancer: an analysis of provincial cancer registry data
    Tran, K.
    Rahal, R.
    Fung, S.
    Louzado, C.
    Porter, G.
    Xu, J.
    Bryant, H.
    CURRENT ONCOLOGY, 2016, 23 (01) : 56 - 59
  • [46] Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer
    Beard, Clair
    Schultz, Delray
    Loffredo, Marian
    Cote, Kerri
    Renshaw, Andrew A.
    Hurwitz, Mark D.
    D'Amico, Anthony V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (02): : 403 - 407
  • [47] Incidence of prostate cancer in Sri Lanka using cancer registry data and comparisons with the incidence in South Asian men in England
    Ranasinghe, Weranja K. B.
    Sibanda, Thabani
    de Silva, M. V. C.
    Ranasinghe, Tamra I. J.
    Persad, Raj
    BJU INTERNATIONAL, 2011, 108 (8B) : E184 - E189
  • [48] Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy
    Yossepowitch, Ofer
    Eggener, Scott E.
    Serio, Angel M.
    Caruer, Brett S.
    Bianco, Fernando J., Jr.
    Scardino, Peter T.
    Eastham, James A.
    EUROPEAN UROLOGY, 2008, 53 (05) : 950 - 959
  • [49] Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy
    Vainshtein, Jeffrey M.
    Schipper, Matthew
    Vance, Sean
    Feng, Felix Y.
    Olson, Karin B.
    Hamstra, Daniel A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (02): : 173 - 180
  • [50] Trends in the curative treatment of localized prostate cancer after the introduction of prostate-specific antigen: data from the Rotterdam Cancer Registry
    Spapen, SJJC
    Damhuis, RAM
    Kirkels, WJ
    BJU INTERNATIONAL, 2000, 85 (04) : 474 - 480
12345